Sunshine Biopharma, Inc.
SBFM Healthcare Drug Manufacturers Specialty & Generic
Sunshine Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.3 million, up 4.11% from fiscal 2024.
- Revenue
- −1.56%
- EPS
- +70.9%
- Free cash flow
- +49.4%
Quarter to June 2026, against a year earlier
Follow SBFM
Alert me
Sunshine Biopharma, Inc. (SBFM) P/E ratio
Sunshine Biopharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1,015,873× (October 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.3× | (13.63%) |
| 27 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SBFM Sunshine Biopharma, Inc. | n/m |
| SXTC China SXT Pharmaceuticals, Inc. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| RDHL Redhill Biopharma Ltd. compare | n/m |
| IMCC IM Cannabis Corp. compare | n/m |
| PTPI Petros Pharmaceuticals, Inc. compare | n/m |
| BTAIQ BioXcel Therapeutics, Inc. compare | n/m |
| AKAN Akanda Corp. compare | — |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)